VKTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viking Therapeutics Inc (VKTX) is not a strong buy for a beginner, long-term investor at this moment. While the company has promising clinical developments and analyst support, insider selling, lack of strong trading signals, and weak financial performance make it less compelling for immediate investment. Holding off for now is advisable.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 57.98, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key support and resistance levels are S1: 30.86 and R1: 35.092, with the stock currently trading near the pivot point at 32.976.
The company is conducting Phase 3 clinical trials for VK2735, with early trials showing a favorable safety profile. VK2809 met both primary and secondary endpoints in a Phase 2 trial, demonstrating significant effects in treating non-alcoholic fatty liver disease. Participation in investor conferences could enhance visibility.
Stock trend analysis predicts a slight decline in the short term.
In Q4 2025, the company reported no revenue growth and a net loss of -$157.66 million, though net income improved YoY by 345.16%. EPS also improved YoY by 331.25%, but the company remains unprofitable.
Morgan Stanley analyst Michael Ulz recently lowered the price target from $102 to $99 but maintained an Overweight rating, indicating confidence in the stock's long-term potential despite the adjustment.
